Shorts Target VIVUS (VVUS) Following January Pop; May be Entering 'Oversold' Territory
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Trade VVUS Now!
VIVUS, Inc. (Nasdaq: VVUS) is a little pressured today amid new market data on short positions in the stock.
From the end of December through January 15th, short interest on VIVUS rose 11.8 percent to 23.61 million shares. The number is equal to about 23.55 percent of float for VIVUS.
Traders might have been a near-term top in VIVUS after the stock spiked higher on rumors that a big pharmaceutical company might be taking interest. Potentially, $15 might be a key activity point for shorts, though there's no immediate danger of getting above that level with VIVUS trading around $12 recently.
A quick technical note, the 14-day money flow index on VIVUS has shares nearing an oversold state, with the MFI reading at 21 percent.
Recent data out of VIVUS and analysts has Belviq with mixed data in terms of prescription growth.
Peers Arena Pharma (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) also saw some movement. Arena's short interest rose 1.5 percent to 53.37 million shares, or 24.7 percent of float, while Orexigen's short interest fell 4 percent to 8.78 million shares, or 13 percent of float.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
From the end of December through January 15th, short interest on VIVUS rose 11.8 percent to 23.61 million shares. The number is equal to about 23.55 percent of float for VIVUS.
Traders might have been a near-term top in VIVUS after the stock spiked higher on rumors that a big pharmaceutical company might be taking interest. Potentially, $15 might be a key activity point for shorts, though there's no immediate danger of getting above that level with VIVUS trading around $12 recently.
A quick technical note, the 14-day money flow index on VIVUS has shares nearing an oversold state, with the MFI reading at 21 percent.
Recent data out of VIVUS and analysts has Belviq with mixed data in terms of prescription growth.
Peers Arena Pharma (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) also saw some movement. Arena's short interest rose 1.5 percent to 53.37 million shares, or 24.7 percent of float, while Orexigen's short interest fell 4 percent to 8.78 million shares, or 13 percent of float.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Canadian Solar (CSIQ) Continues Higher Following Arbitration Win Over LDK (LDK)
- Sony (SNE) is Early Winner in Battle of Video Game Giants (MSFT)
Create E-mail Alert Related Categories
Technicals, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
